查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988191

脑和脊髓癌市场：2026-2032年全球市场预测（按癌症类型、治疗方法、患者年龄层、最终用户和分销管道划分）

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年脑部和脊髓癌市场价值为 42.1 亿美元，预计到 2026 年将成长至 44.6 亿美元，复合年增长率为 5.98%，到 2032 年将达到 63.3 亿美元。

主要市场统计数据
基准年 2025 42.1亿美元
预计年份：2026年 44.6亿美元
预测年份 2032 63.3亿美元
复合年增长率 (%) 5.98%

策略性地实施临床、监管和营运因素的整合，这些因素正在重塑神经肿瘤学的诊断、治疗和护理服务。

本执行摘要概述了影响脑部和脊髓肿瘤诊疗的最关键的临床、营运和策略主题。分子特征分析和精准医学的进步重新定义了诊断流程，同时也增加了治疗决策的复杂性。同时，不断发展的医疗服务模式以及多学科协作日益重要的作用，正在改变患者在诊断、治疗和復原过程中的体验。

对正在重新定义神经肿瘤治疗模式和相关人员期望的变革性科学、医疗保健服务和政策转变进行清晰的检验。

治疗创新是推动改变的最主要动力，标靶治疗、免疫疗法和先进的放射疗法正在改变传统的治疗流程治疗方法。精准诊断能够将患者按分子特征进行分类，从而製定更个人化的治疗计划，同时也需要整合生物标记检测基础设施和建立新的诊疗路径。这些科学进步与技术和医疗设备的改进相辅相成，例如更安全的手术技术和更精准的立体定位放射治疗系统，这些共同作用降低了併发症率，并扩大了符合治疗条件的患者群体。

对 2025 年美国关税政策变化将如何重塑神经肿瘤治疗方法和医疗设备的供应链、筹资策略和准入动态进行深入分析。

美国2025年实施的关税政策，为脑癌和脊髓癌治疗治疗方法及医疗设备的采购、生产和全球筹资策略带来了新的考量。活性成分、医疗设备及相关耗材的关税调整影响了成本结构，促使各机构重新评估供应商多元化和近岸外包方案。这些政策变化使企业更加关注总到岸成本，并激励奖励建立本地製造伙伴关係和加强合约保护。

高解析度分割分析揭示了肿瘤类型、治疗方法、患者年龄层、医疗保健环境和分销管道如何共同决定临床和商业性优先事项。

基于细分市场的分析揭示了肿瘤生物学特征、治疗方法、年龄层、医疗机构和分销管道等方面的细微需求模式和策略重点。按癌症类型划分，市场分析涵盖星状细胞瘤、室管膜瘤、胶质母细胞瘤、髓母细胞瘤、脑膜瘤、少突胶质细胞瘤和神经鞘瘤，每种癌症都具有独特的临床病程、生物标记特征和影响治疗方法选择的手术考量。按治疗方法划分，涵盖化疗、免疫疗法、放射线治疗、支持性治疗、手术和标靶治疗，其中化疗进一步细分为烷化剂、亚硝基脲类药物和含铂类药物。免疫疗法分为CAR-T细胞疗法和查核点抑制剂，放射线治疗分为体外放射治疗、质子治疗和立体定位放射放射线手术。手术分为开颅手术、雷射消熔和微创切除术。标靶治疗的特点是使用激酶抑制剂和单株抗体。

区域分析整合了美洲、欧洲、中东和非洲以及亚太地区的临床能力、监管复杂性和准入因素，有助于制定优先策略。

区域趋势对脑和脊髓肿瘤的临床能力、法规环境以及先进治疗的机会有显着影响。在美洲，综合性学术中心和专科癌症网络往往能够推动新型外科技术和先进放射治疗方法的早期应用，而与保险公司的谈判和报销政策则影响着商业性应用的速度。区域内的跨国合作有助于参与临床试验和知识交流，但都市区三级医疗机构与区域医疗服务提供者之间仍然存在资源获取方面的差距，这影响着复杂医疗服务的公平性。

竞争考察，重点关注神经肿瘤学领域市场领导的创新组合、策略伙伴关係和实证商业化方法。

神经肿瘤领域的主要企业正透过标靶治疗、先进放射治疗平台和支持性护理解决方案的综合产品组合来脱颖而出。它们的策略行动呈现出几个显着的模式，包括投资精准诊断以确保患者筛选的准确性，与学术机构合作以加速转化研究和临床试验的开展，以及透过许可协议扩大地域覆盖范围并降低研发风险。此外，各企业也积极推动特种化合物和无菌注射剂供应链的垂直整合，以降低供应中断的风险。

为神经肿瘤护理路径领域的行业领导者提供切实可行的优先建议，以加快治疗效果、加强供应链并扩大公平获取途径。

产业领导者应采取平衡的短期和长期措施，以应对临床影响、供应链韧性和公平取得等问题。优先投资生物标记项目和综合诊断，以确保准确筛选患者并最大限度地提高治疗效果。除了分子策略外，还应建立完善的註册登记系统和真实世界数据（REW）项目，以收集神经认知结果和长期生活品质（QOL）指标。这些指标在医保报销讨论和临床医生采纳方面正发挥着越来越重要的作用。

采用透明、严谨的混合方法研究途径，结合文献整合、专家访谈和证据三角检验，以支持策略性结论并找出限制。

本分析采用混合方法研究设计，结合系统性的二手资料研究和针对性的原始研究，以验证检验并弥补证据缺口。二手资料包括同侪审查文献、临床试验註册资讯、监管文件和政策公告，从而全面了解治疗机制、临床终点和监管先例。文献整合优先考虑高品质的随机对照试验、关键医疗设备的评估以及共识指南的更新，为基于最有力证据的临床解读提供支援。

明确整合，强调临床创新、营运韧性和协调政策行动的相互依存的优先事项，这对于改善神经肿瘤学的治疗效果至关重要。

科学创新、不断发展的医疗服务模式和不断变化的政策相互交汇，要求整个神经肿瘤生态系统做出协调一致的回应。儘管先进的诊断技术和新型治疗方法为提高生存率和保护神经功能带来了真正的希望，但要实现这一目标，需要强有力的循证策略、稳健的供应链和公平的医疗服务获取机制。因此，相关人员必须儘早与保险公司展开对话，使临床研发与真实世界数据（REW）的收集相契合，并从病患和医疗系统的角度清晰地展现其价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按癌症类型分類的脑部和脊髓癌市场

  • 星状细胞瘤
  • 室管膜瘤
  • 胶质母细胞瘤
  • 髓母细胞瘤
  • 脑膜瘤
  • 少突胶质细胞瘤
  • 雪旺细胞瘤

第九章：依治疗方法分類的脑部和脊髓癌市场

  • 化疗
    • 烷化剂
    • 亚硝基脲类药物
    • 含铂类药物
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
  • 放射线治疗
    • 外部辐射
    • 质子束疗法
    • 立体定位放射放射线手术
  • 支持性护理
  • 外科手术
    • 开颅手术
    • 雷射消熔
    • 微创切除术
  • 标靶治疗
    • 激酶抑制剂
    • 单株抗体

第十章：依患者年龄层分類的脑部和脊髓癌市场

  • 成人版
  • 老年人
  • 儿童

第十一章：脑和脊髓癌市场：依最终用户划分

  • 门诊手术中心
  • 癌症诊所
  • 居家照护设施
  • 医院

第十二章：脑和脊髓癌市场：依通路划分

  • 诊所药房
  • 医院药房
  • 网路药房
  • 零售药房
  • 专卖店

第十三章：脑和脊髓癌市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 脑和脊髓癌市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 脑和脊髓癌市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国脑癌与脊髓癌市场

第十七章：中国脑脊髓癌市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Novocure Limited
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics A/S
Product Code: MRR-9E71DF483B96

The Brain & Spinal Cord Cancer Market was valued at USD 4.21 billion in 2025 and is projected to grow to USD 4.46 billion in 2026, with a CAGR of 5.98%, reaching USD 6.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.21 billion
Estimated Year [2026] USD 4.46 billion
Forecast Year [2032] USD 6.33 billion
CAGR (%) 5.98%

A strategic introduction to the converging clinical, regulatory, and operational forces that are reshaping diagnosis, treatment, and care delivery in neuro-oncology

This executive summary distills the most consequential clinical, operational, and strategic themes shaping care for brain and spinal cord cancers. Advances in molecular characterization and precision therapeutics have redefined diagnostic pathways while concurrently introducing new complexity into treatment decision-making. At the same time, evolving care-delivery models and greater emphasis on multidisciplinary coordination are shifting how patients experience diagnosis, treatment, and survivorship.

Regulatory pathways are evolving in parallel, with accelerated approvals and adaptive trial designs enabling earlier patient access to novel interventions. These innovations come with heightened requirements for real-world evidence and post-approval data that stakeholders must integrate into lifecycle planning. Equally important are the system-level forces-supply chain fragility, workforce constraints, and payment policy debates-that influence how innovations translate into practice.

Taken together, these dynamics create both opportunity and responsibility for commercial teams, clinical leaders, and payers. This summary presents a structured view of the transformational shifts, tariff-driven supply considerations, segmentation-driven insights, regional distinctions, and competitive behaviors that should inform strategy and investment priorities across the neuro-oncology ecosystem.

A clear-eyed review of the transformative scientific, care-delivery, and policy shifts that are redefining neuro-oncology treatment paradigms and stakeholder expectations

Therapeutic innovation is the most visible driver of change, with targeted agents, immunotherapies, and advanced radiation modalities altering conventional treatment algorithms. Precision diagnostics now stratify patients into molecularly defined cohorts, enabling more personalized regimens but also requiring integrated biomarker testing infrastructure and new care pathways. These scientific advances are complemented by procedural and device improvements, including safer surgical techniques and more precise stereotactic delivery systems, which together reduce morbidity and expand treatment candidacy.

Care delivery is undergoing a parallel transformation. Multidisciplinary tumor boards, virtual care modalities, and decentralized treatment options are increasing access while challenging traditional hospital-centric models. Payers and health systems are experimenting with value-based frameworks and outcomes-based contracting, which emphasize real-world outcomes over traditional procedural volumes. These shifts force manufacturers and providers to demonstrate sustained clinical benefit, manage total cost of care, and invest in longitudinal evidence generation.

Finally, patient expectations and advocacy voices now play a central role in shaping research priorities and regulatory conversations. Patients seek therapies that not only extend survival but preserve neurologic function and quality of life, prompting greater attention to neurocognitive endpoints and supportive care integration. As a result, stakeholders must navigate a more complex, patient-centered landscape that demands agility, cross-sector partnerships, and robust evidence strategies.

An incisive assessment of how United States tariff policy changes in 2025 are reshaping supply chains, sourcing strategies, and access dynamics for neuro-oncology therapies and devices

United States tariff policies enacted in 2025 have introduced new considerations across procurement, manufacturing, and global sourcing strategies for therapies and devices used in brain and spinal cord cancer care. Tariff adjustments on active pharmaceutical ingredients, medical devices, and ancillary supplies affect cost structures and have prompted organizations to reassess supplier diversification and nearshoring options. These policy changes heightened attention to total landed cost and created incentives for local manufacturing partnerships and contractual protections.

Supply chain disruption risk has increased the premium on inventory visibility, multi-sourcing strategies, and strategic stockpiles for critical items such as specialty oncology drugs, implantable devices, and precision radiation components. Manufacturers are responding by redesigning logistics networks, qualifying alternate suppliers, and revising pricing contracts to reflect increased import costs and mitigation investments. Procurement teams and finance leaders are now more actively engaging in scenario planning to quantify tariff-related operational impacts and ensure continuity of patient care.

Regulatory and commercial teams must also account for potential downstream effects on access and reimbursement. Payers may adjust formulary strategies or reimbursement rates in response to higher acquisition costs, while providers could face pressure on margins that affects adoption of newer, higher-cost modalities. Therefore, organizations should prioritize transparent supplier relationships, advocate for policy mechanisms that protect patient access, and develop evidence-based value propositions that reconcile higher unit costs with clinical and economic outcomes.

High-resolution segmentation insights revealing how tumor types, therapeutic modalities, patient age cohorts, care settings, and distribution channels jointly determine clinical and commercial priorities

Segmentation-driven analysis reveals nuanced demand patterns and strategic priorities across tumor biology, therapeutic modality, age demographics, care settings, and distribution channels. Based on Cancer Type, market analysis covers Astrocytoma, Ependymoma, Glioblastoma, Medulloblastoma, Meningioma, Oligodendroglioma, and Schwannoma, each presenting distinct clinical courses, biomarker profiles, and surgical considerations that inform therapeutic choices. Based on Treatment Type, the landscape spans Chemotherapy, Immunotherapy, Radiation Therapy, Supportive Care, Surgery, and Targeted Therapy, with chemotherapy further detailed into Alkylating Agents, Nitrosoureas, and Platinum Based Agents; immunotherapy delineated into CAR T Cell Therapy and Checkpoint Inhibitors; radiation therapy separated into External Beam Radiation, Proton Therapy, and Stereotactic Radiosurgery; surgery differentiated by Craniotomy, Laser Ablation, and Minimally Invasive Resection; and targeted therapy characterized by Kinase Inhibitors and Monoclonal Antibodies.

Patient demographics materially influence clinical and commercial approaches. Based on Patient Age Group, the analysis distinguishes Adult, Geriatric, and Pediatric populations, capturing differences in tumor biology, tolerability, and long-term survivorship needs that drive distinct evidence requirements and service models. Based on End User, care delivery is examined across Ambulatory Surgical Centers, Cancer Clinics, Home Care Settings, and Hospitals, reflecting varied capabilities for delivering complex interventions, managing complications, and coordinating multidisciplinary care. Based on Distribution Channel, the study assesses Clinic Pharmacies, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Stores, recognizing that channel choice affects adherence, specialty drug handling, and patient support programs.

Integrating these segmentation lenses highlights intersections that organizations must prioritize: for example, how geriatric presentations of specific tumor types alter suitability for aggressive surgery or systemic therapy; how pediatric tumor biology drives enrollment in specialized trials; how selection of radiation modality depends on tumor location and patient age; and how distribution channel strategies can either enable or constrain adherence and home-based supportive care programs. These insights support targeted product development, evidence generation, and commercial models that align with the heterogeneous needs across neuro-oncology care pathways.

Regional intelligence synthesizing clinical capacity, regulatory complexity, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform prioritized strategies

Regional dynamics materially influence clinical capacity, regulatory environments, and access to advanced therapies for brain and spinal cord cancers. In the Americas, integrated academic centers and specialized cancer networks often drive early adoption of novel surgical techniques and advanced radiation modalities, while payer negotiations and reimbursement policy shape the pace of commercial uptake. Cross-border collaboration within the region supports clinical trial enrollment and knowledge exchange, but disparities in access persist between urban tertiary centers and community providers, which affects equitable delivery of complex care.

In Europe, Middle East & Africa, regulatory harmonization and regional procurement mechanisms coexist with widely varying health system capacities. High-resource European markets exhibit strong capabilities for precision diagnostics and proton therapy infrastructure, whereas parts of the Middle East and Africa emphasize capacity building, workforce development, and access to essential therapies. Strategic partnerships, technology transfer, and capacity-strengthening initiatives are therefore central to expanding access in these markets. Reimbursement frameworks and national policy priorities influence long-term adoption and the sustainability of advanced modalities.

In the Asia-Pacific region, rapid investments in oncology infrastructure and a growing emphasis on domestic biotech innovation are accelerating availability of targeted agents and advanced radiation services. However, heterogeneous payer systems and regulatory pathways create varying commercial entry considerations. In many jurisdictions, manufacturers must navigate complex local reimbursement criteria, pricing negotiations, and public-private partnerships to achieve broad access. Across regions, stakeholders should tailor evidence generation, access strategies, and manufacturing decisions to reflect local regulatory expectations, clinical practice norms, and infrastructure realities.

Competitive company insights emphasizing innovation portfolios, strategic partnerships, and evidence-driven commercialization approaches that differentiate market leaders in neuro-oncology

Leading companies in the neuro-oncology space are differentiating through integrated portfolios that combine targeted agents, advanced radiation platforms, and supportive care solutions. Strategic behaviors fall into several observable patterns: investment in precision diagnostics to ensure appropriate patient selection; partnerships with academic centers to accelerate translational research and trial enrollment; and licensing agreements that expand geographic reach while mitigating development risk. Firms are also pursuing vertical integration in supply chains for specialty compounds and sterile injectable formulations to reduce disruption risk.

Collaboration models are evolving from simple co-development agreements to multifaceted alliances that include data-sharing frameworks, joint real-world evidence initiatives, and outcomes-based contracting pilots. These arrangements allow organizations to align reimbursement with demonstrated patient benefit and to share both clinical and financial risk. From a commercialization perspective, companies are placing greater emphasis on patient support services, digital engagement tools to improve adherence, and hub-and-spoke distribution models that accommodate the handling needs of complex biologics and cell therapies.

Competitive differentiation increasingly depends on demonstrating long-term neurologic outcomes and value across care episodes rather than single-point efficacy. As a result, corporate strategies that integrate robust evidence generation, adaptive pricing models, and strategic partnerships with provider networks will be better positioned to capture sustained uptake while addressing payer and patient expectations.

Practical and prioritized recommendations for industry leaders to accelerate therapeutic impact, fortify supply chains, and expand equitable access within neuro-oncology care pathways

Industry leaders should pursue a balanced set of near-term and long-term actions that address clinical impact, supply chain resilience, and equitable access. Prioritize investment in biomarker programs and integrated diagnostics to ensure precise patient selection and to maximize therapeutic benefit. Complement molecular strategies with robust registries and real-world evidence programs that capture neurocognitive outcomes and longitudinal quality-of-life measures, which are increasingly central to reimbursement discussions and clinician adoption.

Strengthen supply chains through diversification, qualification of alternate suppliers, and consideration of regional manufacturing partnerships to mitigate tariff and import risks. Build contractual flexibility and inventory visibility into procurement practices to reduce the operational strain of policy shifts. On the commercial front, design patient support models that align with distinct distribution channels and care settings, ensuring that specialty handling, adherence programs, and remote monitoring are embedded within the ambulatory and home-care contexts where appropriate.

Finally, cultivate collaborative ecosystems across industry, providers, and patient advocacy groups to accelerate trial enrollment, align evidence priorities, and advocate for policies that preserve access to high-value interventions. Implementing these steps in concert will enable organizations to convert scientific advances into durable clinical improvements and sustainable commercial outcomes.

A transparent and rigorous mixed-methods research approach that combines literature synthesis, expert interviews, and evidence triangulation to underpin strategic conclusions and acknowledge limitations

The analysis integrates a mixed-methods research design that pairs systematic secondary research with targeted primary engagements to validate findings and fill evidence gaps. Secondary sources included peer-reviewed literature, clinical trial registries, regulatory documents, and policy releases to construct a comprehensive view of therapeutic mechanisms, clinical endpoints, and regulatory precedents. This literature synthesis prioritized high-quality randomized trials, pivotal device evaluations, and consensus guideline updates to ground clinical interpretations in the strongest available evidence.

Primary research comprised interviews with clinical experts, health system leaders, payer representatives, and supply chain professionals to elicit perspectives on adoption barriers, reimbursement dynamics, and operational resilience. Expert input informed scenario planning around tariff impacts, procurement responses, and regional capacity constraints. Evidence synthesis applied thematic coding to reconcile divergent viewpoints and to surface priority areas for strategic action, while sensitivity assessments highlighted dependencies and potential limitations.

Limitations of the methodology include the evolving nature of regulatory decisions and rapidly emerging clinical data that may alter practice patterns. To mitigate these constraints, the study emphasizes transparent assumptions, documents data vintage for key inputs, and identifies areas where ongoing surveillance and periodic updates will be necessary to maintain strategic relevance.

A conclusive synthesis that emphasizes the interdependent priorities of clinical innovation, operational resilience, and collaborative policy action necessary to improve neuro-oncology outcomes

The convergent forces of scientific innovation, evolving care delivery, and shifting policy require coordinated responses across the neuro-oncology ecosystem. Precision diagnostics and novel therapeutics offer genuine promise for improving survival and preserving neurologic function, yet realizing that promise depends on robust evidence strategies, resilient supply chains, and equitable access frameworks. Stakeholders must therefore align clinical development with real-world evidence generation and engage payers early to articulate value in terms that matter to patients and health systems.

Operationally, organizations should focus on supply chain diversification, strategic manufacturing partnerships, and procurement practices that absorb policy shocks while protecting patient continuity of care. Region-specific strategies will be necessary to reflect heterogeneity in regulatory pathways, infrastructure, and reimbursement models. Commercial success will increasingly hinge on integrated offers that combine therapeutics with diagnostics, patient support services, and digital tools that facilitate adherence and outcome measurement.

In summary, transforming advances into durable improvements requires a systems-level perspective that balances innovation with practical implementation. By prioritizing evidence generation, operational resilience, and collaborative engagement, stakeholders can accelerate meaningful improvements in outcomes for people affected by brain and spinal cord cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain & Spinal Cord Cancer Market, by Cancer Type

  • 8.1. Astrocytoma
  • 8.2. Ependymoma
  • 8.3. Glioblastoma
  • 8.4. Medulloblastoma
  • 8.5. Meningioma
  • 8.6. Oligodendroglioma
  • 8.7. Schwannoma

9. Brain & Spinal Cord Cancer Market, by Treatment Type

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Nitrosoureas
    • 9.1.3. Platinum Based Agents
  • 9.2. Immunotherapy
    • 9.2.1. CAR T Cell Therapy
    • 9.2.2. Checkpoint Inhibitors
  • 9.3. Radiation Therapy
    • 9.3.1. External Beam Radiation
    • 9.3.2. Proton Therapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Supportive Care
  • 9.5. Surgery
    • 9.5.1. Craniotomy
    • 9.5.2. Laser Ablation
    • 9.5.3. Minimally Invasive Resection
  • 9.6. Targeted Therapy
    • 9.6.1. Kinase Inhibitors
    • 9.6.2. Monoclonal Antibodies

10. Brain & Spinal Cord Cancer Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Brain & Spinal Cord Cancer Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cancer Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Brain & Spinal Cord Cancer Market, by Distribution Channel

  • 12.1. Clinic Pharmacies
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies
  • 12.5. Specialty Stores

13. Brain & Spinal Cord Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain & Spinal Cord Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain & Spinal Cord Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain & Spinal Cord Cancer Market

17. China Brain & Spinal Cord Cancer Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. bluebird bio, Inc.
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Dr. Reddy's Laboratories Ltd.
  • 18.12. Eisai Co., Ltd.
  • 18.13. Eisai Inc.
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Genentech, Inc.
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Illumina, Inc.
  • 18.18. Johnson & Johnson Services, Inc
  • 18.19. Merck & Co., Inc.
  • 18.20. Nektar Therapeutics
  • 18.21. Novartis AG
  • 18.22. Novocure Limited
  • 18.23. Pfizer Inc.
  • 18.24. Regeneron Pharmaceuticals, Inc.
  • 18.25. Shimadzu Corporation
  • 18.26. Siemens Healthineers
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Y-mAbs Therapeutics A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)